Where do Relay Therapeutics, Inc.'s ratios come from?

Every ratio is computed from Relay Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Profitability
Operating margin	-2,776.6%-805pp	-1,971.5%+1,943pp	-3,914.4%+191pp	-4,105.6%+673pp	-4,778.9%-1,057pp
Net margin	-2,554.1%-754pp	-1,800.5%+1,761pp	-3,561.4%+167pp	-3,728.4%+613pp	-4,341.5%-967pp
EBITDA margin	-2,749.9%-802pp	-1,948.3%+1,915pp	-3,863%+184pp	-4,046.8%+663pp	-4,710.2%-1,043pp
Returns
Return on equity	-40%+1.1pp	-41.1%0.0pp	-41.1%+5.1pp	-46.2%-0.8pp	-45.5%-1.3pp
Return on assets	-36.4%+0.7pp	-37%+0.2pp	-37.2%+4.3pp	-41.5%-0.9pp	-40.6%-1.3pp
Return on invested capital	-51.8%-2.1pp	-49.7%+1.1pp	-50.9%+7.0pp	-57.9%-2.3pp	-55.6%-1.0pp
Efficiency
Asset turnover	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Liquidity
Current ratio	22.1×-0.5×	22.6×+3.5×	19.1×-1.8×	20.9×+1.0×	20×+4.0×
Quick ratio	22.1×-0.5×	22.6×+3.5×	19.1×-1.8×	20.9×+1.0×	20×+4.0×
Cash ratio	6.9×+3.6×	3.3×+0.5×	2.8×-0.7×	3.5×+1.0×	2.5×+0.1×
Leverage
Debt-to-equity	0×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Debt-to-assets	0×0.0×	0.1×0.0×	0×0.0×	0×0.0×	0.1×0.0×
Valuation
Market capitalization	$1.78B+21.3%	$1.47B+62.9%	$899.99M+58.6%	$567.48M+27.8%	$444.15M-35.6%
Enterprise value	$1.61B+13.5%	$1.41B+68.1%	$841.75M+72.6%	$487.72M+22.6%	$397.76M-35.2%
Price / sales	166.6×+71.1×	95.5×-12.2×	107.7×+39.8×	67.9×+10.1×	57.8×-11.1×
Price / book	2.8×+0.2×	2.6×+1.1×	1.5×+0.6×	0.9×+0.2×	0.6×-0.3×
EV / sales	150.4×+58.2×	92.1×-8.6×	100.7×+42.4×	58.4×+6.6×	51.8×-9.5×
Earnings yield	-15.3%+3.5pp	-18.9%+14.2pp	-33.1%+21.8pp	-54.9%+20.2pp	-75.1%-26.1pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Relay Therapeutics, Inc.'s ratios come from?: Every ratio is computed from Relay Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.